Attention is focused on negotiating the drug price of Zolgensma, a one-shot treatment and the most expensive drug in Korea. Conflicts are in full swing between the government to set the lowest price and pharmaceutical companies to be recognized as much as possible for new drugs.
Zolgensma is a gene therapy approved in May last year. It is used for a severe and rare disease called SMA. This disease is causing muscles to gradually shrink. Based on the most serious type of SMN type 1, motor neurons are damaged more than 95% within six months of microtreatment, and 90% die before the age of two. Prior to Zolgensma, there were treatments for spinal muscular atrophy such as Spinraza and Evrysdi, but Zolgensma is spec